Advertisement

Studies of Renal Eicosanoid Synthesis In Vivo and In Vitro

  • Giovanni Ciabattoni
  • Francesco Pugliese
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 259)

Abstract

The kidney is a rich source of cyclooxygenase and lipoxygenase enzymes which catalyze the conversion of arachidonic acid to prostaglandins (PGs), thromboxane (Tx) and leukotrienes. These eicosanoids are autacoids which have been shown to have biologic actions in vitro and in vivo. Although the biochemical analysis of renal eicosanoids in vitro has been easily accomplished, their identification and quantification in vivo have been shown to be more complex. The present chapter describes some analytic methodologies for the study of the renal eicosanoid system, both in vitro and in vivo. In vitro studies of eicosanoid synthesis by glomerular cells in response to injury will be addressed. In vivo measurement of primary (unmetabolized) PGs and Tx in humans and clinical conditions and pharmacological evidence in favor of a renal origin of the urinary PGI2 breakdown product, i.e., 6-keto-PGF and TxB2, will be discussed.

Keywords

Mesangial Cell Urinary Excretion Rate Eicosanoid Synthesis Renal Origin Sulindac Sulfide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. Schlondorff and R. Ardaillou, Prostaglandin and other arachidonic acid metabolites in the kidney, Kidney Int. 29:108–119 (1986).PubMedGoogle Scholar
  2. 2.
    R.A. Stahl, M. Paravicini, P. Schollmeyer, Angiotensin II stimulation of PGE2 and 6-keto-PGF formation by isolated human glomeruli, Kidnev Int. 26:30–34 (1984).Google Scholar
  3. 3.
    J. Sraer, N. Ardaillou, J.D. Sraer, R. Ardaillou, In vitro prostaglandin synthesis by human glomeruli and papillae, Prostaglandins 23:855–864 (1983).Google Scholar
  4. 4.
    A. Hassid, M. Konieczkowski, M.J. Dunn, Prostaglandin synthesis in isolated rat kidney glomeruli, Proc. Natl. Acad. Sci. USA 76:1155–1159 (1979).PubMedGoogle Scholar
  5. 5.
    J. Sraer, J.D. Sraer, D. Chansel, F. Russo-Marie, B. Kouznetzova, R. Ardaillou, Prostaglandin synthesis by isolated rat renal glomeruli, Mol. Cell Endocrinol. 16:29–37 (1979).PubMedGoogle Scholar
  6. 6.
    A.S. Petrulis, M. Aikawa, M.J. Dunn, Prostaglandin and thromboxane synthesis by rat glomerular epithelial cells, Kidney Int. 20:469–474 (1981).PubMedGoogle Scholar
  7. 7.
    J. Sraer, J. Foidart, D. Chansel, P. Mahieu, B. Kouznetzova, R. Ardaillou, Prostaglandin synthesis by mesangial and epithelial glomerular cultured cells, FEBS Letters 15:420–424 (1979).Google Scholar
  8. 8.
    J.I. Kreisberg, M.J. Karnowsky, L. Levine, Prostaglandin production by homogeneous cultures of rat glomerular epithelial and mesangial cells, Kidney Int. 22:355–359 (1982).PubMedGoogle Scholar
  9. 9.
    L.A. Scharschmidt and M.J. Dunn, Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and argi-nine vasopressin, J. Clin. Invest. 71:1756–1764 (1983).PubMedGoogle Scholar
  10. 10.
    N. Ardaillou, Y. Hagege, M.P. Nivez, R. Ardaillou, D. Schlondorff, Vasoconstrictor-evoked prostaglandin synthesis in cultured human mesangial cells, Am. J. Physiol. 248:F240–F246 (1985).PubMedGoogle Scholar
  11. 11.
    N. Ardaillou, M.P. Nivez, G. Striker, R. Ardaillou, Prostaglandin synthesis by human glomerular cells in culture, Prostaglandins 26:778–784 (1983).Google Scholar
  12. 12.
    D. Lovett, G.M. Hansen, K. Resch, D. Gemsa, Activation of glomerular mesangial cells by terminal complement components: stimulation of prostanoid and interleukin 1-like factor release, (abstract), Immunobiol. 168:34–35 (1984).Google Scholar
  13. 13.
    G.M. Hansen, K. Rother, J. Gunther, S. Filsinger, R.B. Sterzel, Terminal complement components stimulate prostanoid production of cultured glomerular epithelial cells, (abstract), Kidney Int. 29:277 (1986).Google Scholar
  14. 14.
    L. Baud, M.P. Nivez, D. Chansel, R. Ardaillou, Stimulation by oxygen free radicals of prostaglandin production by rat renal glomeruli, Kidney Int. 20:332–345 (1981).PubMedGoogle Scholar
  15. 15.
    D. Schlondorff, J.A. Satriano, J. Hagege, J. Perez, L. Baud, Effect of platelet activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells, J. Clin. Invest. 73:1227–1231 (1984).PubMedGoogle Scholar
  16. 16.
    D. Lovett, D. Gemsa, K. Resch, Stimulation of mesangial cell prostanoid secretion by interleukin 1, (abstract), Kidney Int. 19:282 (1986).Google Scholar
  17. 17.
    J.E. Stork, M.A. Rahman, M.J. Dunn, Eicosanoids in experimental and human renal disease, Am. J. Med. 80 (suppl.1A): 34–35 (1986).PubMedGoogle Scholar
  18. 18.
    M.W. Sciler, M.A. Venkatachalam, R.S. Contran, Glomerular epithelium: structural alterations induced by polycations, Science 189:390–393 (1975).Google Scholar
  19. 19.
    W.M. Deen, B.D. Myers, B.M. Brenner, The glomerular barrier to macromolecules: theoretical and experimental considerations, in: “Contemporary Issues In Nephrology,” B.M. Brenner and J.H. Stein, eds., Churchill Livingstone, New York, Vol. 9, pp. 1–29 (1982).Google Scholar
  20. 20.
    B.M. Brenner, T.H. Hostetter, D. Humes, Molecular basis of proteinuria of glomerular origin, N. Engl. J. Med. 298:826–833 (1978).PubMedGoogle Scholar
  21. 21.
    E.B. Blau and J.E. Haas, Glomerular sialic acid and proteinuria in human renal disease, Lab. Investu 28:477–481 (1973).Google Scholar
  22. 22.
    D. Kerjaschki, A.T. Vernillo, M.G. Farquhar, Reduced sialylation of podocalixin — the major sialoprotein of the rat kidney glomerulus — in aminonucleoside nephrosis, Am. J. Pathol. 118:343–349 (1985).PubMedGoogle Scholar
  23. 23.
    R.L. Vernier, D.J. Klein, S.P. Sisson, J.D. Mahan, T.R. Oegema, D.M. Brown, Heparan sulfate-rich anionic sites in the human glomerular basement membrane. Decreased concentration in congenital nephrotic syndrome, N. Engl. J. Med. 309:1001–1009 (1983).PubMedGoogle Scholar
  24. 24.
    J.B. Foidart, Y.S. Picard, R.J. Winaud, P.R. Mahieu, Tissue culture of normal rat glomeruli: glycosaminoglycan biosynthesis by homogenous epithelial and mesangial cell populations, Renal Physiol. 3:169–173 (1980).PubMedGoogle Scholar
  25. 25.
    J.L. Barnes, S.P. Levine, M.A. Venkatachaiam, Binding of platelet factor four (PF4) to glomerular polyanions, Kidney Int. 25:759–765 (1984).PubMedGoogle Scholar
  26. 26.
    L. Jorgensen, M.F. Glynn, T. Hovig, E.A. Murphy, M.R. Buchanan, J.F. Mustard, Renal lesions and rise in blood pressure caused by adenosine diphosphate-induced platelet aggregation in rabbits, Lab. Invest. 23: 347–357 (1970).PubMedGoogle Scholar
  27. 27.
    J.L. Olson, Role of heparin as a protective agent following reduction of renal mass, Kidney Int. 25:376–382 (1984).PubMedGoogle Scholar
  28. 28.
    J.I. Kreisberg, R.L. Hoover, M.J. Karnowsky, Isolation and characterization of rat glomerular epithelial cells in vitro, Kidney Int. 14:21–30 (1978).PubMedGoogle Scholar
  29. 29.
    A.K. Singh, B.S. Kasinath, E.J. Lewis, Discrete anionic domains on the surface of glomerular epithelial cells (GEC) (abstract), Clin. Res. 34:609A (1986).Google Scholar
  30. 30.
    G. Remuzzi, L. Imberti, M. Rossini, C. Morelli, C. Carminati, M.G. Cattaneo, T. Bertani, Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis, J. Clin. Invest. 75:94–101 (1985).PubMedGoogle Scholar
  31. 31.
    L.J. Rosenzweig and Y.S. Kanvar, Removal of sulphated (heparan sulphate) or nonsulphated (hyaluronic acid) glycosaminoglycans results in increased permeability of the glomerular basement membrane to 125I-bovine serum albumin, Lab. Invest. 47:177–184 (1982).PubMedGoogle Scholar
  32. 32.
    V.M. Vehaskari, E.R. Root, F.G. Germuth, A.M. Robson, Glomerular charge and urinary protein excretion: effects of systemic and intrarenal polycation infusion in the rat, Kidney Int. 22:127–135 (1982).PubMedGoogle Scholar
  33. 33.
    W.T. Shier, D. Dubourdieu, J.P. Durkin, Polycations as prostaglandin synthesis inducers. Stimulation of arachidonic acid release and prostaglandin synthesis in cultured fibroblasts by poly(L-lysine) and other synthetic polycations, Biochim. Biophys. Acta 793:238–250 (1984).PubMedGoogle Scholar
  34. 34.
    R.A. Stahl, M. Kudelka, M. Paravicini, P. Schollmeyer, Prostaglandin and thromboxane formation in glomeruli from rats with reduced renal mass, Nephron 42:252–257 (1986).PubMedGoogle Scholar
  35. 35.
    T.H. Hostetter, J.L. Olson, H.G. Rennke, M.A. Venkatachalam, B.M. Brenner, Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation, Am. J. Physiol. 241:F85–F93 (1981).PubMedGoogle Scholar
  36. 36.
    M. Schambelan, S. Blake, J. Sraer, M. Beres, M.P. Nivez, F. Wahbe, Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus, J. Clin. Invest. 75:404–412 (1985).PubMedGoogle Scholar
  37. 37.
    T.H. Hostetter, J.L. Troy, B.M. Brenner, Glomerular hemodynamics in experimental diabetes mellitus, Kidney Int. 19:410–415 (1981).PubMedGoogle Scholar
  38. 38.
    I.M. Goldstein, C.L. Malmsten, H. Kindhal, H.B. Kaplan, D. Radmark, B. Samuelsson, G. Weisman, Thromboxane generation by human peripheral blood polymorphonuclear leukocytes, J. Exp. Med. 148:787–792 (1979).Google Scholar
  39. 39.
    J. Morley, M.A. Bray, R.W. Jones, D.H. Nugteren, D.A. Van Dorp, Prostaglandin and thromboxane production by human and guinea-pig macrophages and leukocytes, Prostaglandins 17:730–736 (1979).Google Scholar
  40. 40.
    P.S. Needleman, S. Moneada, S. Bunting, J.R. Vane, M. Hamberg, B. Samuelsson, Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides, Nature 261:558–560 (1976).PubMedGoogle Scholar
  41. 41.
    J.I. Kreisberg, D.B. Wayne, M.J. Karnowsky, Rapid and focal loss of negative charge associated with mononuclear cell infiltration early in nephrotoxic serum nephritis, Kidney Int. 16:290–300 (1979).PubMedGoogle Scholar
  42. 42.
    E.A. Lianos, G.A. Andres, M.J. Dunn, Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis, J. Clin. Invest. 72:1439–1448 (1983).PubMedGoogle Scholar
  43. 43.
    G. Camussi, C. Tetta, G. Segoloni, R. Coda, A. Vercellone, Localization of neutrophil cationic proteins and loww of anionic charges in glomeruli of patients with systemic lupus erythematosus, Clin. Immun. Immunopathol. 24:299–314 (1982).Google Scholar
  44. 44.
    C. Patrono, G. Ciabattoni, G. Remuzzi, E. Gotti, S. Bombardieri, O. Di Munno, G. Tartarelli, G.A. Cinotti, B.M. Simonetti, A. Pierucci: Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus, J. Clin. Invest. 76:1011–1018 (1985).PubMedGoogle Scholar
  45. 45.
    D.M. Brown, D.J. Klein, A.F. Michael, T.R. Oegema, 35S-glycosaminoglycan and 35S-glycopeptide metabolism by diabetic glomeruli and aorta, Diabetes 31:418–425 (1982).PubMedGoogle Scholar
  46. 46.
    M.P. Cohen, M.L. Surma, Effects of diabetes on in vivo metabolism of S-labeled glomerular basement membrane, Diabetes 33:8–12 (1984).PubMedGoogle Scholar
  47. 47.
    M.J. Dunn, Renal prostaglandins, in: “Renal Endocrinology,” M.J. Dunn, ed., Williams and Wilkins, Baltimore, pp. 1–74 (1983).Google Scholar
  48. 48.
    C. Patrono and F. Pugliese, The involvement of arachidonic acid metabolism in the control of renin release, J. Endocrinol. Invest. 3:193–201 (1980).PubMedGoogle Scholar
  49. 49.
    C. Patrono, Å. Wennmalm, G. Ciabattoni, J. Nowak, F. Pugliese, G.A. Cinotti, Evidence for an extrarenal origin of urinary prostaglandin E2 in healthy men, Prostaglandins 18:623–629 (1979).PubMedGoogle Scholar
  50. 50.
    M. Hamberg and B. Samuelsson, The structure of the major urinary metabolite of prostaglandin E2 in man, J. Am. Chem. Soc. 91:2177–2178 (1969).PubMedGoogle Scholar
  51. 51.
    M. Hamberg and B. Samuelsson, On the metabolism of prostaglandin E1 and E2 in man, J. Biol. Chem. 246:6713–6721 (1971).PubMedGoogle Scholar
  52. 52.
    E. Granström and B. Samuelsson, On the metabolism of PGF in female subjects, J. Biol. Chem. 246:5254–5263 (1971).PubMedGoogle Scholar
  53. 53.
    E. Granström and B. Samuelsson, On the metabolism of prostaglandin F in female subjects. II. Structures of six metabolites, J. Biol. Chem. 246:7470–7485 (1971).PubMedGoogle Scholar
  54. 54.
    J.C. Frölich, T.W. Wilson, B.J. Sweetman, M. Smigel, A.S. Nies, K. Carr, J.T. Watson, J.A. Oates, Urinary prostaglandins: identification and origin, J. Clin. Invest. 55:763–770 (1975).PubMedGoogle Scholar
  55. 55.
    R.D. Zipser and K. Martin, Urinary excretion of arterial blood prostaglandins and thromboxane in man, Am. J. Physiol. 242:E171–177 (1982).PubMedGoogle Scholar
  56. 56.
    G.A. FitzGerald, A.K. Pedersen, C. Patrono, Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease, Circulation 67:1174–1177 (1983).PubMedGoogle Scholar
  57. 57.
    F. Pugliese and G. Ciabattoni, Investigations of renal arachidonic acid metabolites by radioimmunoassay, in: “Prostaglandins and The Kidney,” M.J. Dunn, C. Patrono, G.A. Cinotti, eds., Plenum Press, New York, pp. 83–98 (1983).Google Scholar
  58. 58.
    G. Ciabattoni, F. Pugliese, E. Pinea, G.A. Cinotti, A. De Salvo, M.A. Satta, C. Patrono, Biologic and méthodologie variables affecting urinary prostaglandin measurement, in: “Advances in Prostaglandin, Thromboxane and Leukotriene Research,” B. Samuelsson, P.W. Ramwell, R. Paoletti, eds., Raven Press, New York, Vol. 6, pp. 207–212 (1980).Google Scholar
  59. 59.
    G. Ciabattoni, F. Pugliese, G.A. Cinotti, C. Patrono, Methodologie problems in the radioimmunoassay of prostaglandin E2 and F in human urine, in: “Radioimmunoassay of Drugs and Hormones in Cardiovascular Medicine,” A. Albertini, M. Da Prada, B.A. Peskar, eds., Elsevier/North Holland, Amsterdam, pp. 265–280 (1979).Google Scholar
  60. 60.
    C. Patrono, F. Pugliese, G. Ciabattoni, P. Patrignani, A. Maseri, S. Chierchia, B.A. Peskar, G.A. Cinotti, B.M. Simonetti, A. Pierucci, Evidence for a direct stimulatory effect of prostacyclin on renin release in man, J. Clin. Invest. 69:231–239 (1982).PubMedGoogle Scholar
  61. 61.
    C. Patrono, Validation criteria for radioimmunoassay, in: “Radioimmunoassay in Basic and Clinical Pharmacology,” C. Patrono and B.A. Peskar, eds., Handb. Exp. Pharm., Springer-Verlag, Berlin, Vol. 82, pp. 213–225 (1987).Google Scholar
  62. 62.
    G.A. FitzGerald, A.R. Brash, P.F. Falardeau, J.A. Oates, Estimated rate of prostacyclin secretion into the circulation of normal man, J. Clin. Invest. 68:1272–1276 (1981).PubMedGoogle Scholar
  63. 63.
    C. Patrono, G. Ciabattoni, F. Pugliese, A. Pierucci, I.A. Blair, G.A. FitzGerald, Estimated rate of thromboxane secretion into the circulation, J. Clin. Invest. 77:590–594 (1986).PubMedGoogle Scholar
  64. 64.
    J.A. Lawson, C. Patrono, G. Ciabattoni, G.A. FitzGerald, Long-lived enzymatic metabolites of TxB2 in the human circulation, Anal. Biochem. 155:198–205 (1986).PubMedGoogle Scholar
  65. 65.
    G. Ciabattoni, F. Pugliese, A. Pierucci, B.M. Simonetti, C. Patrono, Fractional conversion of thromboxane B2 to urinary 11-dehydro-thromboxane B2 in man, J. Clin. Invest., submitted for publication.Google Scholar
  66. 66.
    G. Ciabattoni, J. Maclouf, F. Catella, G.A. FitzGerald, C. Patrono, Radioimmunoassay of 11-dehydro-thromboxane B2 in human plasma and urine, Biochim. Biophys. Acta 918:293–297 (1987).PubMedGoogle Scholar
  67. 67.
    G. Ciabattoni, F. Pugliese, G.A. Cinotti, G. Stirati, R. Ronci, G. Castrucci, A. Pierucci, C. Patrono, Characterization of furosemide-induced activation of the renal prostaglandin system, Eur. J. Pharmacol. 60:181–187 (1979).PubMedGoogle Scholar
  68. 68.
    J.R. Gill, Jr., J.C. Frölich, R.E. Bowden, A.A. Taylor, H.R. Keiser, W.S. Hannsjorg, J.A. Oates, F.C. Bartter, Bartter’s syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis, Am. J. Med. 61:43–51 (1976).PubMedGoogle Scholar
  69. 69.
    H.G. Güllner, C. Cerletti, F.C. Bartter, J.B. Smith, J.R. Gill, Jr., Prostacyclin overproduction in Bartter’s syndrome, Lancet 11:767–768 (1976).Google Scholar
  70. 70.
    M.L. Watson, J.R. Gill, R.A. Branch, J.A. Oates, A.R. Brash, Systemic prostaglandin In synthesis is normal in patients with Bartter’s syndrome, Lancet II:368–369 (1983).Google Scholar
  71. 71.
    L.J. Roberts, B.J. Sweetman, J.A. Oates, Metabolism of thromboxane B2 in man, J. Biol. Chem. 256:8384–8393 (1981).PubMedGoogle Scholar
  72. 72.
    G. Ciabattoni, G.A. Cinotti, A. Pierucci, B.M. Simonetti, M. Manzi, F. Pugliese, P. Barsotti, G. Pecci, F. Taggi, C. Patrono, Effects of sulindac and ibuprofen in patients with chronic glomerular disease, N. Engl. J. Med. 310:279–283 (1984).PubMedGoogle Scholar
  73. 73.
    G. Ciabattoni, F. Pugliese, G.A. Cinotti, C. Patrono, Renal effects of anti-inflammatory drugs, Eur. J. Rheumatol. Inflam. 3:210–221 (1980).Google Scholar
  74. 74.
    P. Patrignani, P. Filabozzi, C. Patrono, Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects, J. Clin. Invest. 69:1366–1372 (1982).PubMedGoogle Scholar
  75. 75.
    F. Catella, F. Pugliese, P. Patrignani, P. Filabozzi, G. Ciabattoni, C. Patrono, Differential platelet and renal effects of sulfinpyrazone in man, (Abstract), Clin. Res. 32:239A (1984).Google Scholar
  76. 76.
    P. Patrignani, P. Filabozzi, F. Catella, F. Pugliese, C. Patrono, Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism, J. Pharmacol. Exp. Ther. 228:472–477 (1984).PubMedGoogle Scholar
  77. 77.
    C. Patrono, G. Ciabattoni, P. Filabozzi, F. Catella, L. Forni, M. Segni, P. Patrignani, F. Pugliese, B.M. Simonetti, A. Pierucci, Drugs, Prostaglandin and Renal Function, in: “Advances in Prostaglandin, Thromboxane and Leukotriene Research,” G.G. Neri Serneri, J.C. McGiff, R. Paoletti, G.N.R. Born, eds., Raven Press, New York, Vol. 3, pp. 131–139 (1985).Google Scholar
  78. 78.
    P. Patrignani, F. Catella, P. Filabozzi, F. Pugliese, A. Pierucci, B.M. Simonetti, L. Forni, M. Segni, C. Patrono, Differential effects of OKY-046, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin endoperoxide metabolism, (Abstract), Clin. Res. 32:246A (1984).Google Scholar
  79. 79.
    G.J. Roth, N.S. Stanford, P.W. Majerus, Acetylation of prostaglandin synthase by aspirin, Proc. Natl. Acad. Sci. USA 72:3073–3077 (1975).PubMedGoogle Scholar
  80. 80.
    F.J. Van der Ouderaa, M. Buytenhek, D.H. Nugteren, D.A. Van Dorp, Acetylation of prostaglandin endoperoxide synthase with acetylsalicylic acid, Eur. J. Biochem. 109:1–8 (1980).Google Scholar
  81. 81.
    C. Patrono, G. Ciabattoni, P. Patrignani, P. Filabozzi, E. Pinca, M.A. Satta, D. Van Dorne, G.A. Cinotti, F. Pugliese, A. Pierucci, B.M. Simonetti, Evidence for a renal origin of urinary TxB2 in health and disease, in: “Advances in Prostaglandin, Thromboxane and Leukotriene Research,” B. Samuelsson, R. Paoletti, P. Ramwell, eds., Raven Press, New York, Vol. 11, pp. 493–498 (1983).Google Scholar
  82. 82.
    G.A. FitzGerald, J.A. Oates, J. Hawiger, R.L. Maas, L.J. Roberts II, J.A. Lawson, A.R. Brash, Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man, J. Clin. Invest. 71:676–688 (1983).PubMedGoogle Scholar
  83. 83.
    G. Ciabattoni, A.H. Boss, L. Daffonchio, J. Daugherty, G.A. FitzGerald, F. Catella, F. Dray, C. Patrono, Radioimmunoassay measurement of 2,3-dinor metabolites of prostacyclin and thromboxane in human urine, in: “Advances in Prostaglandin, Thromboxane and Leukotriene Research,” B. Samuelsson, R. Paoletti, P.W. Ramwell, eds., Raven Press, New York, Vol. 17, pp. 598–602 (1987).Google Scholar
  84. 84.
    C. Patrono, G. Ciabattoni, E. Pinca, F. Pugliese, G. Castrucci, A. De Salvo, M.A. Satta, B.A. Peskar, Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects, Thromb. Res. 17:317–327 (1980).PubMedGoogle Scholar
  85. 85.
    D.E. Duggan, L.E. Hare, C.A. Ditzler, B.W. Lei, C. Kwan, The disposition of sulindac, Clin. Pharmacol. Ther. 21:326–335 (1977).PubMedGoogle Scholar
  86. 86.
    J.R. Sedor, S.L. Williams, A.N. Chremos, C.L. Johnson, M.J. Dunn, Effects of sulindac and indomethacin on renal prostaglandin synthesis, Clin. Pharmacol. Ther. 36:85–91 (1984).PubMedGoogle Scholar
  87. 87.
    J.L. Nadler, M. McKay, V. Campese, J. Vrbanac, R. Horton, Evidence that prostacyclin modulates the vascular actions of calcium in man, J. Clin. Invest. 77:1278–1284 (1986).PubMedGoogle Scholar
  88. 88.
    R. Vriesendorp, D. De Zeeuw, P.E. De Jong, A.J.M. Donker, J.J. Pratt, G.K. van der Hem, Reduction of urinary protein and prostaglandin E2 excretion in the nephrotic syndrome by nonsteroidal anti-inflammatory drugs, Clin. Nephrol. 25:105–110 (1986).PubMedGoogle Scholar
  89. 89.
    A. Salvetti, R. Pedrinelli, P. Alberici, A. Magagna, B. Abdel-Haq, The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients, Br. J. Clin. Pharmacol. 17:108S-111S (1984).PubMedGoogle Scholar
  90. 90.
    A. Salvetti, R. Pedrinelli, A. Magagna, P. Ugenti, Differential effects of selective and non-selective prostaglandin-synthesis inhibition on the pharmacological responses to Captopril in patients with essential hypertension, Clin. Sci. 63:261S-263S (1982).Google Scholar
  91. 91.
    I.B. Puddey, L.J. Beilin, R. Vandongen, R. Banks, I. Rouse, Differential effects of sulindac and indomethacin on blood pressure in treated essential hypertensive subjects, Clin. Sci. 69:327–336 (1985).PubMedGoogle Scholar
  92. 92.
    CD. Mistry, C.J. Lote, R. Gokal, W.J. Currie, M. Vandenburg, M.P. Mallick, Effects of sulindac on renal function and prostaglandin synthesis in patients with moderate chronic renal insufficiency, Clin. Sci. 70:501–505 (1986).PubMedGoogle Scholar
  93. 93.
    F. Guarner, C. Guarner, J. Prieto, I. Colina, J. Quiroga, J. Casas, R. Freixa, J. Posello, E. Gelpi, J. Balanzo, Increased synthesis of systemic prostacyclin in cirrhotic patients, Gastroenterology 90:687–694 (1986).PubMedGoogle Scholar
  94. 94.
    G. Laffi, G. La Villa, M. Pinzani, G. Ciabattoni, P. Patrignani, M. Mannelli, F. Cominelli, P. Gentilini, Altered renal and platelet arachidonic acid metabolism in cirrhosis, Gastroenterology 90:274–282 (1986).PubMedGoogle Scholar
  95. 95.
    U.G. Svendsen, J. Gerstoft, T.M. Hansen, P. Christensen, I.B. Lorenzen, The renal excretion of prostaglandins and changes in plasma renin during treatment with either sulindac or naproxen in patients with rheumatoid arthritis and thiazide-treated heart failure, J. Rheumatol. 11:779–782 (1984).PubMedGoogle Scholar
  96. 96.
    D.C. Brater, S. Anderson, B. Baird, W.B. Campbell, Effects of ibuprofen, naproxen and sulindac on prostaglandins in men, Kidney Int. 27: 66–73 (1985).PubMedGoogle Scholar
  97. 97.
    D.G. Roberts, J.G. Gerber, J.S. Barnes, G.O. Zerbe, A.S. Nies, Sulindac is not renal-sparing in man, Clin. Pharmacol. Ther. 38:258–265 (1985).PubMedGoogle Scholar
  98. 98.
    K.J. Berg and T. Talseth, Acute effects of sulindac and indomethacin in chronic renal failure, Clin. Pharmacol. Ther. 37:447–452 (1985).PubMedGoogle Scholar
  99. 99.
    G. Laffi, G. Daskalopoulos, I. Kronborg, W. Hsueh, P. Gentilini, R.D. Zipser, Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac, Gastroenterology 90:182–187 (1986).PubMedGoogle Scholar
  100. 100.
    E. Quintero, P. Gines, V. Arroyo, A. Rimola, J. Camps, J. Gaya, A. Guevara, M. Rodamilans, J. Rodes, Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites, Nephron 42:298–303 (1986).PubMedGoogle Scholar
  101. 101.
    C. Patrono and M.J. Dunn, The clinical significance of inhibition of renal prostaglandin synthesis, Kidney Int. 32:1–12 (1987).PubMedGoogle Scholar
  102. 102.
    G. Ciabattoni, A.H. Boss, P. Patrignani, F. Catella, B.M. Simonetti, A. Pierucci, F. Pugliese, P. Filabozzi, C. Patrono, Effects of sulindac on renal and extrarenal eicosanoid synthesis, Clin. Pharmaco1. Ther. 41:380–383 (1987).Google Scholar
  103. 103.
    A. Kirstein Pedersen and P. Jakobsen, Sulfinpyrazone metabolism during long-term therapy, Br. J. Clin. Pharmacol. 11:597–603 (1981).Google Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • Giovanni Ciabattoni
    • 1
    • 2
  • Francesco Pugliese
    • 1
    • 2
  1. 1.Department of PharmacologyCatholic University School of MedicineRomeItaly
  2. 2.II Clinica MedicaCattedra di Nefrologia Rome University “La Sapienza,”RomeItaly

Personalised recommendations